The souring economy put a dent in the white-hot leveraged buyout market for the med-tech industry, a panel of fund managers said yesterday at the AdvaMed 2011 conference in Washington.
The European banks crisis, an uncertain regulatory environment in the U.S. and a looming new tax on medical devices all have mixed into a toxic stew that’s choking the LBO market, which had surged back since the economic slump in 2009.